COLTRO, GIACOMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.364
AS - Asia 1.841
EU - Europa 1.608
SA - Sud America 209
AF - Africa 46
OC - Oceania 23
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.092
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.323
RU - Federazione Russa 743
CN - Cina 598
SG - Singapore 519
IT - Italia 300
HK - Hong Kong 241
KR - Corea 185
BR - Brasile 169
VN - Vietnam 126
IE - Irlanda 124
SE - Svezia 77
FI - Finlandia 76
DE - Germania 65
FR - Francia 63
CH - Svizzera 61
IN - India 57
GB - Regno Unito 31
NL - Olanda 27
AU - Australia 23
ID - Indonesia 23
CA - Canada 22
JO - Giordania 19
AR - Argentina 17
MX - Messico 13
JP - Giappone 11
BD - Bangladesh 8
ZA - Sudafrica 8
CI - Costa d'Avorio 7
IQ - Iraq 7
NG - Nigeria 7
PL - Polonia 7
ES - Italia 6
MA - Marocco 6
PH - Filippine 6
PK - Pakistan 6
AT - Austria 5
BJ - Benin 5
UA - Ucraina 5
UZ - Uzbekistan 5
CO - Colombia 4
EC - Ecuador 4
KE - Kenya 4
PY - Paraguay 4
TN - Tunisia 4
TR - Turchia 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
CL - Cile 3
KZ - Kazakistan 3
LB - Libano 3
BG - Bulgaria 2
DZ - Algeria 2
IL - Israele 2
JM - Giamaica 2
KH - Cambogia 2
LI - Liechtenstein 2
LU - Lussemburgo 2
MY - Malesia 2
NP - Nepal 2
OM - Oman 2
RO - Romania 2
SA - Arabia Saudita 2
UY - Uruguay 2
VE - Venezuela 2
AL - Albania 1
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
BT - Bhutan 1
BW - Botswana 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
GR - Grecia 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
LT - Lituania 1
LV - Lettonia 1
MN - Mongolia 1
MT - Malta 1
NO - Norvegia 1
PE - Perù 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
YT - Mayotte 1
Totale 6.092
Salva come PNG Salva come JPEG
Città #
Santa Clara 703
Singapore 392
Ashburn 346
Hefei 213
Hong Kong 208
Seoul 185
San Jose 166
Dublin 124
Fairfield 81
Moscow 74
Chandler 68
Beijing 67
Bern 61
Ho Chi Minh City 48
Los Angeles 46
Florence 45
The Dalles 44
Kent 43
Buffalo 41
Helsinki 38
Woodbridge 37
Cambridge 36
Lauterbourg 36
Seattle 35
Munich 32
Altamura 31
Dallas 30
Lawrence 30
New York 29
Turku 28
Council Bluffs 27
Mumbai 27
Hanoi 26
Houston 26
Melbourne 23
Wilmington 23
Shanghai 22
Milan 19
Boston 18
Paris 18
Princeton 18
Jakarta 16
London 16
São Paulo 16
Washington 12
Ann Arbor 11
Bengaluru 11
Tianjin 10
Falkenstein 9
Lappeenranta 9
Montreal 9
Tokyo 9
Brooklyn 8
Sesto Fiorentino 8
Siena 8
Abidjan 7
Abuja 7
Bremen 7
Chennai 7
Chicago 7
Orem 7
Rio de Janeiro 7
Rome 7
Amsterdam 6
Da Nang 6
Frankfurt am Main 6
Pian di Scò 6
Toronto 6
West Jordan 6
Yubileyny 6
Atlanta 5
Boardman 5
Cervia 5
Cotonou 5
Fiesole 5
Johannesburg 5
Medford 5
Modena 5
San Diego 5
Tashkent 5
Warsaw 5
Castel Maggiore 4
Clifton 4
Denver 4
Haiphong 4
Hillsboro 4
Mexico City 4
Napoli 4
Pune 4
Redondo Beach 4
Altopascio 3
Amman 3
Baghdad 3
Belo Horizonte 3
Biên Hòa 3
Bologna 3
Bắc Ninh 3
Casablanca 3
Catania 3
Chengdu 3
Totale 3.935
Salva come PNG Salva come JPEG
Nome #
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 262
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 211
A life-threatening ruxolitinib discontinuation syndrome 193
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 191
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis 189
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis 186
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative 180
Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature 175
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis 172
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 171
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 167
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis 166
Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients 164
Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients 163
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features 163
The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions 155
Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency≤ 1% 154
Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis 153
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera 152
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 145
Mutations and thrombosis in essential thrombocythemia 140
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis 139
Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients 134
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis 130
Hematologic Neoplasms Associated with Down Syndrome: Cellular and Molecular Heterogeneity of the Diseases 130
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis 130
Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment 130
Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia 127
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates 126
Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities 124
Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Adult Patients 121
Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms 118
The safety of JAK kinase inhibitors for the treatment of myelofibrosis 114
Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP 110
Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib 109
Integration of molecular information in risk assessment of patients with myeloproliferative neoplasms 109
Thrombotic risk correlates with mutational status in true essential thrombocythemia 106
A challenging diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement 104
Response to erythropoiesis‐stimulating agents in patients with WHO‐defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T) 103
Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis 103
Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms 90
Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients 88
Clinical and Prognostic Correlates of the Reticulin-Collagen-Osteosclerosis (RCO) Score in Primary Myelofibrosis 73
Combinatorial BCL2/BCL2L1 expression predicts clinical response to ruxolitinib in myelofibrosis 10
Totale 6.180
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.080
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.080
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 0 0 0 0 0 0 0 0 9 3
2021/2022110 2 1 3 1 4 5 0 22 14 1 23 34
2022/2023559 34 87 36 23 56 90 69 21 35 15 16 77
2023/2024445 18 25 56 18 39 75 11 79 12 50 43 19
2024/20252.227 57 206 122 318 562 341 80 107 82 81 129 142
2025/20262.537 304 419 383 263 247 70 300 124 132 196 99 0
Totale 6.180